Eur J Neurol. 2012 May 12. doi: 10.1111/j.1468-1331.2012.03745.x. [Epub ahead of print]
Jesús S, Pérez I, Cáceres-Redondo MT, Carrillo F, Carballo M, Gómez-Garre P, Mir P.
Abstract
BACKGROUND:
Uric
acid (UA) is thought to have an antioxidant effect on the central
nervous system and may also prevent cerebral damage induced by
oxidative stress. Our study aimed to investigate whether patients with
Parkinson's disease had lower serum UA concentrations than controls and
whether UA concentration was related to clinical parameters of the
disease.
METHODS:
We included 161 patients with
Parkinson's disease and 178 controls from southern Spain. UA
concentration was compared between these two groups. Clinical
parameters including severity of the disease were related to serum uric
acid.
RESULTS:
Patients with Parkinson's disease showed
statistically significant lower serum UA concentrations than controls.
Serum UA concentration was lower in patients with Parkinson's disease
in severe stages (4 and 5) than in those in moderate stage (2)
according to the modified Hoehn and Yahr scale. Other clinical
parameters were not related to serum UA concentration, except for
levodopa equivalent daily dose that was associated with lower serum UA
concentration in men.
CONCLUSIONS:
Our study produced
consistent findings that UA might have a protective effect against
Parkinson's disease and could influence its clinical progression.
No comments:
Post a Comment